期刊
EXPERT REVIEW OF VACCINES
卷 14, 期 4, 页码 537-549出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/14760584.2015.982101
关键词
anti-tumor immunity; BLT1; cancer; cancer immune surveillance; CD8(+) T cells; chemokine receptors; chemokines; CTL migration; CXCR3; leukotriene B4
类别
资金
- NIH R01 [CA138623]
- Kentucky Lung Cancer Research Program
- James Graham Brown Cancer Center
- University of Louisville School of Medicine
Cancer immunotherapy has recently emerged as an important treatment modality. FDA approval of provenge, ipilimumab and pembrolizumab has started to deliver on the long awaited promise of cancer immunotherapy. Many new modalities of immunotherapies targeting cytotoxic T lymphocytes (CTLs) responses, such as adoptive cell therapies and vaccines, are in advanced clinical trials. In all these immunotherapies, migration of CTLs to the tumor site is a critical step for achieving therapeutic efficacy. However, inefficient infiltration of activated CTLs into established tumors is increasingly being recognized as one of the major hurdles limiting efficacy. Mechanisms that control migration of CTLs to tumors are poorly defined. In this review, the authors discuss the chemoattractants and their receptors that have been implicated in endogenous- or immunotherapy-induced CTL recruitment to tumors and the potential for targeting these pathways for therapeutic efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据